FDA cites ‘deficiencies’ in Ascendis’ application for parathyroid drug, jeopardizing potential approval
The FDA is asking for more information about Ascendis Pharma’s drug for hypoparathyroidism, a rare condition in which the body doesn’t produce enough of a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
